Aimmune Therapeutics (NASDAQ:AIMT) Rating Lowered to Buy at BidaskClub

Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

AIMT has been the topic of a number of other research reports. Goldman Sachs Group set a $27.00 target price on Aimmune Therapeutics and gave the company a “hold” rating in a report on Friday, October 25th. HC Wainwright assumed coverage on Aimmune Therapeutics in a report on Thursday, December 19th. They set a “neutral” rating and a $33.00 price objective on the stock. Credit Suisse Group downgraded Aimmune Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $31.59 to $30.00 in a report on Friday, December 13th. Wedbush reissued a “buy” rating and set a $79.00 price objective on shares of Aimmune Therapeutics in a report on Thursday, January 9th. Finally, ValuEngine downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 3rd. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $42.10.

Shares of AIMT stock traded up $1.14 during trading hours on Tuesday, reaching $36.51. The company’s stock had a trading volume of 314,452 shares, compared to its average volume of 943,946. The firm’s 50 day simple moving average is $31.65 and its 200-day simple moving average is $24.86. The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -9.95 and a beta of 0.02. Aimmune Therapeutics has a fifty-two week low of $16.95 and a fifty-two week high of $36.74. The company has a quick ratio of 4.64, a current ratio of 4.64 and a debt-to-equity ratio of 0.33.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($1.03). During the same period last year, the company posted ($0.89) earnings per share. Sell-side analysts predict that Aimmune Therapeutics will post -3.98 earnings per share for the current year.

In related news, insider Douglas T. Sheehy sold 10,000 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $33.03, for a total transaction of $330,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel C. Md Adelman sold 20,000 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $30.04, for a total value of $600,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,000 shares of company stock worth $1,631,100. 13.75% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its position in Aimmune Therapeutics by 11.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock worth $109,234,000 after purchasing an additional 535,072 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Aimmune Therapeutics by 4.6% in the 2nd quarter. Vanguard Group Inc. now owns 3,706,394 shares of the biotechnology company’s stock worth $77,167,000 after acquiring an additional 164,038 shares in the last quarter. Eventide Asset Management LLC raised its position in shares of Aimmune Therapeutics by 11.1% in the 3rd quarter. Eventide Asset Management LLC now owns 3,084,000 shares of the biotechnology company’s stock worth $64,579,000 after acquiring an additional 309,000 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Aimmune Therapeutics by 2.4% in the 2nd quarter. Victory Capital Management Inc. now owns 1,121,811 shares of the biotechnology company’s stock worth $23,357,000 after acquiring an additional 26,690 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in shares of Aimmune Therapeutics by 12.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 752,358 shares of the biotechnology company’s stock worth $15,754,000 after acquiring an additional 82,798 shares in the last quarter. 82.31% of the stock is owned by institutional investors and hedge funds.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Story: Price-Sales Ratio

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.